Zevra Therapeutics’ Miplyffa (arimoclomol) has received FDA approval for treating neurological symptoms associated with Neimann-Pick disease type C (NPC) in adults and children. This is the first drug approved for this rare genetic disease, offering hope to patients suffering from its progressive neurological symptoms and organ dysfunction.